Intravenous Fosaprepitant Versus Oral Aprepitant for Children Receiving Highly Emetogenic Chemotherapy: An Investigator‐Initiated Randomized, Open‐Label, Non‐Inferiority Trial
Intravenous Fosaprepitant Versus Oral Aprepitant for Children Receiving Highly Emetogenic Chemotherapy: An Investigator‐Initiated Randomized, Open‐Label, Non‐Inferiority Trial
Sameer Bakhshi, Deepam Pushpam, Azgar Abdul Rasheed, Anu Theresa Joison et al.
Journal
Pediatric Blood & Cancer
Topics
Nausea and vomiting management
article
Intravenous Fosaprepitant Versus Oral Aprepitant for Children Receiving Highly Emetogenic Chemotherapy: An Investigator‐Initiated Randomized, Open‐Label, Non‐Inferiority Trial
Sameer Bakhshi, Deepam Pushpam, Azgar Abdul Rasheed, Anu Theresa Joison, Santhosh E. Kumar, Swetambri Sharma, Ashwati S. Pillai, Manraj Singh, Atul Batra, Sreenivas Vishnubhatla, Shuvadeep Ganguly
article en
Abstract
No abstract available for this paper.
Publication Tag
Pediatric Blood & Cancer
Institutions
Mayo Clinic (US), Regional Cancer Center, Thiruvananthapuram (IN), DR. B.R.A. Institute Rotary Cancer Hospital (IN), Jawaharlal Institute of Post Graduate Medical Education and Research (IN), All India Institute of Medical Sciences (IN)